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Abstract
Background:  The objective was to evaluate the effects of rosiglitazone on iliac arteries of
hypercholesterolemic rabbits undergoing balloon catheter injury in the contralateral iliac arteries.
Methods: White male rabbits were fed a hypercholesterolemic diet for 6 weeks and divided into
two groups as follows: rosiglitazone group, 14 rabbits treated with rosiglitazone (3 mg/Kg body
weight/day) during 6 weeks; and control group, 18 rabbits without rosiglitazone treatment. All
animals underwent balloon catheter injury of the right iliac artery on the fourteenth day of the
experiment.
Results: There was no significant difference in intima/media layer area ratio between the control
group and the rosiglitazone group. Rosiglitazone did not reduce the probability of lesions types I,
II, or III (72.73% vs. 92.31%; p = 0.30) and types IV or V (27.27% vs. 7.69%; p = 0.30). There were
no differences in the extent of collagen type I and III deposition or in the percentage of animals with
macrophages in the intima layer. The percentage of rabbits with smooth muscle cells in the intima
layer was higher in rosiglitazone group (p = 0.011).
Conclusion: These findings demonstrate that rosiglitazone given for 6 weeks did not prevent
atherogenesis at a vessel distant from the injury site.
Background
Balloon angioplasty is a common intervention for treat-
ment of blood vessel stenosis, particularly in coronary
vasculature. However, the balloon directly inflicts signifi-
cant trauma to the vascular endothelium, which is evi-
denced by an immediate loss of endothelial-dependent
relaxation, and is associated with a concomitant induc-
tion of a smooth muscle cell (SMC) proliferation and
neointimal formation [1]. There is some evidence that
balloon injury can induce physiological changes at sites
anatomically distant from, as well as at the site of the
injury itself [1,2]. Accorsi et al [2] presented potential sys-
temic adverse effects of angioplasty in a rat injury model.
In this experiment the authors showed that following bal-
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loon injury, there was a delayed hyper-reactivity to both
phenylephrine and angiotensin II in contralateral rat
carotid arteries, occurring between 4–7 and 15–30 days,
respectively, and thereafter returning to control levels.
Peroxisome proliferator-activated receptor γ (PPAR-γ) is a
member of the nuclear receptor superfamily, which when
activated by thiazolidinedione (TZD) insulin sensitizers,
regulates the expression of genes that control lipid and
glucose homeostasis, thus modulating the major meta-
bolic disorders predisposing to atherosclerosis [3-5]. All
of the major cells in the vasculature express PPAR-γ,
including endothelial cells, vascular smooth muscle cells
(VSMC), and monocytes/macrophages [3,4]. Rosiglita-
zone, a PPAR-γ agonist, can prevent neointimal formation
and reduce macrophage content in the carotid artery of a
mouse injury model of type 2 diabetes [6]. In a combined
diabetes-atherosclerosis mouse model, Levi et al [7] sug-
gested a direct anti-atherogenic effect of rosiglitazone on
the arterial wall, despite higher lipid levels and similar
glucose levels. The use of PPAR-γ agonist rosiglitazone
(RZG) for 5 weeks in hypercholesterolemic rabbits exert
significant endothelial protection by antioxidative and
antinitrative effects [8]. The purpose of the present study
was to investigate the effects of rosiglitazone on the con-
tralateral unballooned iliac artery in hypercholestero-
lemic rabbits.
Methods
Thirty-two white adult male rabbits (New Zealand),
weighing 2.596 ± 530 Kg, were used for this experiment.
Animals were handled in compliance with the Guiding
Principles in the Care and Use of Animals. Protocol
approval was obtained from the Pontifical Catholic Uni-
versity Animal Research Committee. During first 14 days,
the animals were fed a hypercholesterolemic diet (1%
cholesterol-Sigma-Aldrich®). Subsequently, they were fed
a 0.5% cholesterol diet until sacrifice (45 days). The ani-
mals were divided into two groups as follows: control
group (CG), 18 rabbits without RGZ; and rosiglitazone
group (RG), 14 rabbits treated with RGZ administered by
oral gavage (3 mg/Kg body weigh/day) during all the
experiment.
Vascular injury
All the animals underwent balloon catheter (20 × 3 mm/
5 atm/5 min) injury of the right iliac artery on the four-
teenth day of the experiment. Anesthesia was induced
with ketamine (Vetanarcol®-König – 3.5 mg/Kg) and intra-
muscular xylazine (Coopazine®- Coopers – 5 mg/Kg).
After the procedure animals had received intramuscular
analgesics for 3 days (25 mg/day of flunixin – Banamine®
-Schering-Plough) and intramuscular antibiotics for 4
days (100 mg/day of oxitetracyclin – TormicinaP®-
Toruga). Rabbits were sacrificed by a lethal barbiturate
dose on day 45 and their unballooned contralateral iliac
arteries were removed for immunohistochemical and his-
tological analysis.
Quantitative histopathology
Histological analysis was done by an experienced pathol-
ogist (LN) who was unaware of the RGZ treatment, with a
microscope attached to the Image Pro-plus® 4.5 Software
(Media Cybernetics Inc. Siver Spring, MD. USA). Histo-
morphometric parameters were performed with calcula-
tion of the intima/media layer area ratio (the area of the
intima layer divided by the area of the media layer)
according to method described by Phillips et al [5]. The
quantification of type I and type III collagen area was
made by the Sirius red polarization method [9]. Athero-
sclerotic lesions were analyzed and classified according to
Stary et al [10-12].
Immunohistochemistry
Tissue preparation and immunohistological techniques
were performed according to the manufacturer's instruc-
tions included in the kits (Dako Corporation, Carpinteria,
Calif). Sections were stained for macrophage cells using
primary monoclonal antibody RAM-11 (Dako®, Carpinte-
ria, CA), and for alpha-actin smooth muscle cells with pri-
mary polyclonal antibody HHF-35 (Dako®, Carpinteria,
CA). For qualitative immunohistochemical comparisons
of macrophage and smooth muscle cell presence in the
intima area, sections were computed and scored in per-
centages of animals with cells in the unballooned iliac
artery. For quantitative immunohistochemical compari-
sons of macrophage or smooth muscle cell content in
intima area, sections were computed and scored in per-
centages of cells in the intima.
Blood chemistry
Blood samples were obtained on first day experiment,
immediately before balloon catheter injury, and immedi-
ately before sacrifice by cardiac puncture. Clinical labora-
tory assessment included fasting serum glucose, total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), and triglycerides (TGC). Measurements were
done using an automated system (Abbott Architect
ci8200; Abbott Laboratories, Abbott Park, III).
Statistical analysis
The calculation of sample size was done based on the
study of Wang Zhao-hui, Luo Feng and Liu Xiao-mei [13].
The main variable of interest was considered to be the
ratio between the intima layer and the media layer. To
detect a minimum difference of 0.15 between the averages
of groups, with a significance level of 5% and power of the
test by 80%, the minimum number of animals in each
group of the study was defined as 12. Categorical variables
were expressed as percentages and continuous variables
were expressed as mean ± SD and medians. Shapiro-WilksThrombosis Journal 2008, 6:4 http://www.thrombosisjournal.com/content/6/1/4
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test was used for testing sample normality. For quantita-
tive parameters, the Student t-test and Mann-Whitney
nonparametric test were used for the comparison between
CG and RG. Fisher's exact test was used for qualitative or
categorical variables. Statistical significance was indicated
by a value of p < 0.05. Analyses were performed using Sta-
tistica/W version 5.1 (StatSoft, Tulsa, Okla.).
Results
Metabolic and lipid profiles
Rabbit's weight did not differ between groups (data not
shown). Baseline glucose, total cholesterol, HDL- choles-
terol and triglycerides levels were equal in both groups
before initiation of the diet. A graded elevation in TC and
glucose levels was observed from the initial phase through
the sacrifice in both groups. At the time of euthanasia the
glucose levels did not differ between groups. Higher levels
of TGC and HDL-C and lower levels of TC were observed
in RG versus CG at the time of sacrifice (Table 1).
Histomorphometry
There was no significant difference in intima/media layer
area ratio between CG and RG (Figure 1). According to
histological classification proposed by Stary et al, rosigli-
tazone did not reduce the probability of lesions types I, II,
or III (72.73% vs. 92.31%; p = 0.30) and types IV or V
(27.27% vs. 7.69%; p = 0.30) when compared to CG (Fig-
ure 1). In addition, there were no differences in the extent
of collagen type I and III deposition between CG and RG
(data not shown).
Immunohistochemistry
There was no statistically significant difference in the per-
centage of animals with macrophages in the intima layer
between CG and RG (33.4% vs. 71.5%; p = 0.07). The per-
centage of animals with smooth muscle cells in intima
layer was higher in RG when compared with CG (22.3%
vs. 71.5%; p = 0.011). (Table 2). (Figures 2 and 3).
Discussion
In this study, we analyze the histological changes caused
by catheter balloon injury and the potential effects of ros-
iglitazone on a vessel distant from the injury site. We used
rabbits with six-fold increased cholesterol levels at the
time of vascular injury and fourteen-fold increased levels
at the time of euthanasia. Previous studies have shown
that PPARγ is highly expressed in macrophage foam cells
from atherosclerotic lesions and has been demonstrated
in cultured macrophages to both positively and negatively
regulate genes implicated in the development of athero-
sclerosis [14,15]. Collins et al [16] demonstrated that
PPARγ troglitazone inhibited lesion formation in male
low density lipoprotein receptor-deficient mice fed with
either a high-fat diet or a high-fructose diet by decreasing
the accumulation of macrophages in intimal xanthomas.
In contrast, Hennuyer et al [5] reported that in a dyslipi-
demic nondiabetic murine model (E2-KI mice), PPARα,
but not PPARγ (rosiglitazone and pioglitazone), activators
protect against macrophage foam cell formation. This can
be explained by the fact that in the presence of severe dys-
lipidemia PPARγ activation in macrophages is insufficient
to reverse the pro-atherogenic process. Chawla et al [17],
using LDLR -/- mice, showed that in addition to lipid
uptake, PPARγ regulates a pathway of cholesterol efflux.
Another possible explanation for these findings, raised by
the authors, is that homeostasis cholesterol control by
activation of PPARγ may differ between species [15,18].
Wang et al [13] showed a reduction in aorta intima/media
ratio in hypercholesterolemic rabbits receiving RGZ (0.5
mg/weight) for 6 weeks. Our data showed no significant
difference regarding the percentage of animals with inti-
mal macrophages, initial and advanced atherosclerotic
lesions, and intima/media layer ratio in contralateral iliac
artery with the use of RGZ. This can be explained, in part,
by the fact that PPARγ agonist stimulate expression of the
scavenger receptor CD36 in macrophages that facilitates
uptake of oxidized LDL and contributes to the develop-
ment of atherosclerosis [18-20]. Li et al [14,15] reported
that rosiglitazone and GW7845 strongly inhibited the
development of atherosclerosis in LDL receptor-deficient
male, despite their proatherogenic effects evidenced by
increased expression of the CD36 scavenger receptor in
arterial wall. In the present study, we did not evaluate the
expression of CD36. It has also been suggested that the
Table 1: Metabolic and lipid profiles (mean ± sd).
CG RG P value
Baseline TC (mg/dl) 39.67 ± 12.76 38.93 ± 10.92 0.837
*HDL-C (mg/dl) *25 (10 – 44) *19 (12 – 36) 0.156
TGC (mg/dl) 85.28 ± 51,60 81.36 ± 33,44 0.807
Glucose (mg/dl) 121.89 ± 15.40 117.36 ± 11,19 0.362
Sacrifice TC (mg/dl) 864.22 ± 269.85 638.29 ± 269.54 0.026
*HDL-C (mg/dl) *28 (13 – 125) *54 (27 – 85) 0.020
TGC (mg/dl) 117.61 ± 75.07 192.50 ± 87.21 0.01
Glucose (mg/dl) 195.83 ± 70.15 237.86 ± 87.43 0.142
(*) HDL-C values are expressed as median, maximum and minimum.Thrombosis Journal 2008, 6:4 http://www.thrombosisjournal.com/content/6/1/4
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effects of RGZ in foam cell formation and atherosclerosis
may differ in the degree of insulin resistance [5,21]. We
found a graded and significant elevation of glucose levels
from the initial phase through the sacrifice in both groups
with and without RGZ and we believe that it could be sec-
ondary to the development of some degree of insulin
resistance although this was not evaluated in the present
study. Wang et al [13] did not show a reduction of blood
glucose level in hypercholesterolemic rabbits receiving
RGZ for 6 weeks, as in the present study. Furthermore, we
also observed a significant elevation of triglycerides and
HDL-C at the time of euthanasia in RGZ group. The effects
of thiazolidinediones on triglycerides have been some-
what more variable. Decreases in triglyceride levels have
been more frequently observed with pioglitazone than
with rosiglitazone. We cannot rule out that these effects
on glucose and triglycerides were due to chance, as our
evaluation period was short and the sample was relatively
Graphics of intima/media layer ratio and histologic classification of lesions Figure 1
Graphics of intima/media layer ratio and histologic classification of lesions. A. Intima/media layer area ratio. B. Incidence of 
lesions types according with histological classification.Thrombosis Journal 2008, 6:4 http://www.thrombosisjournal.com/content/6/1/4
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small. These findings are quite controversial in the litera-
ture [7,8,13]. Other studies with different animals-models
[1,2,22] have related a potential increase in cell replica-
tion far from the injury site and endothelial dysfunction
in contralateral artery after balloon catheter injury. We
have found a significant increase of animals with SMC in
the intima layer of unballooned iliac arteries. While in
other studies there is evidence of antiatherogenic effects of
these drugs in different animal models and in diabetic
patients [23-28], this is the first study to report a lack of
antiatherogenic effects of a PPARγ agonist in a vessel dis-
tant from the injury site. We cannot rule out that our his-
tological analysis reflected a short period of exposure to
RGZ. In addition, we did not evaluated the artery vasodil-
atation, peroxynitrite (ONOO-) formation, endothelial
nitric oxide (NO), or the expression of vasodilator-stimu-
lated phosphoprotein VASP (P-VASP) that should be
assessed in future studies. The presence of diabetes accel-
erates the process of atherosclerosis and cardiovascular
disease is the leading cause of death and the major cause
of morbidity [29-31]. Thus, it is necessary to enhance our
knowledge about the mechanisms of action of thiazolid-
inediones largely used in type 2 diabetes, particularly ros-
iglitazone that has been the focus of extensive discussion
in recent publications. Nissen and Wolski [29] published
a meta-analysis showing a significant increase in the risk
of myocardial infarction and an increase in cardiovascular
death of borderline significance in patients with diabetes
receiving RGZ. Singh et al [32] also published a meta-
analysis showing a significantly increased risk of myocar-
dial infarction and heart failure among patients with
impaired glucose tolerance or type 2 diabetes using rosigl-
itazone for at least 12 months, with no significantly
increased risk of cardiovascular mortality. Lipscombe et al
[33], in a nested case-control analysis of a retrospective
cohort study, found that in diabetes patients with an age
of 66 years or older, RGZ treatment was associated with an
increased risk of congestive heart failure, acute myocardial
infarction, and mortality when compared with other com-
bination oral hypoglycemic agent treatments. The mecha-
nism for the apparent increase in myocardial infarction
and death from cardiovascular causes associated with RGZ
Table 2: Percentage of macrophage and SMC in intima layer.
CG (N/%) RG (N/%)
Animals with macrophage (p = 0.07) 6 (33.4%) 10 (71.5%)
≤ 10% cells 3 (16.6%) 5 (35.7%)
10–25% cells 1 (5.5%) 0
25–50% cells 2 (11.1%) 5 (35.7%)
50–75% cells 0 0
> 75% cells 0 0
Animals with SMC (p = 0,01) 4 (22.3%) 10 (71.5%)
≤ 10% cells 1 (5.5%) 3 (21.4%)
10–25% cells 0 0
25–50% cells 2 (11.1%) 5 (35.7%)
50–75% cells 1 (5.5%) 2 (14.2%)
> 75% cells 0 0
Percentage of animals with and without smooth muscle cells in the intima layer Figure 2
Percentage of animals with and without smooth muscle cells in the intima layer.
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remains uncertain. However, to apply the effects of thia-
zolidinediones on atherosclerosis in experimental models
to the clinical practic is difficult and largely depends on
the validity of the model. In the next three years, we hope
that the final results of the studies RECORD and BARI-2D
[30,34], specifically evaluating cardiovascular effects of
RGZ, will provide useful insights.
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